Reviewing Non-Dopaminergic Mechanisms for Positive and Negative Schizophrenia Symptom Management
Reviewing Non-Dopaminergic Mechanisms for Positive and Negative Schizophrenia Symptom Management is organized by CME Institute of Physicians Postgraduate Press, Inc. (PPP).
Activity opens: 08/08/2023
Activity expires: 08/31/2024
Program Description:
Join Leslie Citrome, MD, MPH, Jonathan Meyer, MD, and Bethany Yeiser, president of the CURESZ foundation, for an engaging discussion of emerging, non-dopaminergic therapies for individuals experiencing the positive and negative symptoms associated with schizophrenia. In a live lecture format, Dr. Citrome first examines the longstanding, unmet needs of patients of schizophrenia before providing an overview of the dopaminergic treatment paradigm that has dominated care for over seventy years. To reinforce the issues tied to the current standard of care, Bethany shares her challenges living with schizophrenia, which included a period of homelessness and constant changes in medication. Dr. Meyer then documents the history behind the development of alternative drugs with presynaptic, antipsychotic mechanisms, such as muscarinic agonists and TAAR1 agonists. The presentation closes with an assessment of phase 2 clinical trial data supporting the use of xanomeline-trospium and ulotaront in patients with schizophrenia and speculation regarding their positioning in treatment algorithms.
Learning Objectives:
After completing this educational activity, you should be able to:
• Outline current medication classes used in the treatment of schizophrenia
• Articulate side effect development and negative symptom control challenges associated with standard-of-care antipsychotics
• Review the latest research describing the biologic rationale of novel non-dopaminergic pathways in schizophrenia
• Analyze emerging clinical trial data for non-dopamine-targeting schizophrenia therapies